Proteomics

Dataset Information

0

TCR-engineered T-cells directed against Ropporin-1 constitute a safe and effective treatment for triple-negative breast cancer in near-clinical models


ABSTRACT: Triple-negative breast cancer (TNBC) shows an urgent need for new therapies. We discovered Ropporin-1 (ROPN1) as a target to treat TNBC with T-cells. ROPN1 showed high and homogenous expression in 90% of primary and metastatic TNBC but not in healthy tissues. HLA-A2-binding peptides were detected via immunopeptidomics and predictions and used to retrieve T-cell receptors (TCRs) from naïve repertoires. Following gene introduction into T-cells and stringent selection, we retrieved a highly specific TCR directed against the epitope FLYTYIAKV that did not recognize non-cognate epitopes from alternative source proteins. Notably, this TCR mediated killing of three-dimensional tumoroids in vitro and tumor cells in vivo and outperformed standard-of-care drugs. Finally, the T-cell product expressing this TCR and manufactured using a clinical protocol fulfilled standard safety and efficacy assays. Collectively, we have identified and preclinically validated ROPN1 as a target and anti-ROPN1 TCR T-cells as a treatment for the vast majority of TNBC patients.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Michal Bassani-Sternberg  

LAB HEAD: Michal Bassani-Sternberg

PROVIDER: PXD055042 | Pride | 2024-08-30

REPOSITORIES: Pride

Dataset's files

Source:

Similar Datasets

2019-11-27 | PXD014017 | Pride
2019-07-31 | PXD009925 | Pride
2019-10-16 | PXD012308 | Pride
2020-09-02 | PXD020011 | Pride
2023-03-21 | PXD034772 | Pride
2020-03-27 | PXD013649 | Pride
2024-08-30 | PXD047641 | Pride
2021-04-13 | PXD022950 | Pride
2023-04-07 | PXD034773 | Pride
2017-12-15 | PXD006939 | Pride